
Clara Marco-Marin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6613000/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Discovery of 3H-pyrrolo[2,3-c]quinolines with activity against Mycobacterium tuberculosis by allosteric inhibition of the glutamate-5-kinase enzyme. European Journal of Medicinal Chemistry, 2022, 232, 114206.	5.5	7
2	Functional and structural characterization of PIIâ€like protein CutA does not support involvement in heavy metal tolerance and hints at a smallâ€molecule carrying/signaling role. FEBS Journal, 2021, 288, 1142-1162.	4.7	14
3	Nitrogen storage regulation by PII protein: lessons learned from taxonomic outliers. FEBS Journal, 2020, 287, 439-442.	4.7	1
4	Δ ¹ â€Pyrrolineâ€5â€carboxylate synthetase deficiency: An emergent multifaceted urea cycleâ€relate disorder. Journal of Inherited Metabolic Disease, 2020, 43, 657-670.	ed 3.6	20
5	P5CS expression study in a new family with <i>ALDH18A1</i> â€associated hereditary spastic paraplegia SPG9. Annals of Clinical and Translational Neurology, 2019, 6, 1533-1540.	3.7	14
6	The PII-NAGK-PipX-NtcA Regulatory Axis of Cyanobacteria: A Tale of Changing Partners, Allosteric Effectors and Non-covalent Interactions. Frontiers in Molecular Biosciences, 2018, 5, 91.	3.5	43
7	Understanding N-Acetyl-L-Glutamate Synthase Deficiency: Mutational Spectrum, Impact of Clinical Mutations on Enzyme Functionality, and Structural Considerations. Human Mutation, 2016, 37, 679-694.	2.5	26
8	<i>ALDH18A1</i> gene mutations cause dominant spastic paraplegia SPG9: loss of function effect and plausibility of a dominant negative mechanism. Brain, 2016, 139, e3-e3.	7.6	42
9	Understanding pyrrolineâ€5â€carboxylate synthetase deficiency: clinical, molecular, functional, and expression studies, structureâ€based analysis, and novel therapy with arginine. Journal of Inherited Metabolic Disease, 2012, 35, 761-776.	3.6	44
10	Congenital hypomyelinating neuropathy due to a novel MPZ mutation. Journal of the Peripheral Nervous System, 2011, 16, 347-352.	3.1	12
11	The site for the allosteric activator GTP of <i>Escherichia coli</i> UMP kinase. FEBS Letters, 2009, 583, 185-189.	2.8	2
12	The crystal structure of the complex of PII and acetylglutamate kinase reveals how PII controls the storage of nitrogen as arginine. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17644-17649.	7.1	113
13	A Novel Two-domain Architecture Within the Amino Acid Kinase Enzyme Family Revealed by the Crystal Structure of Escherichia coli Glutamate 5-kinase. Journal of Molecular Biology, 2007, 367, 1431-1446.	4.2	62
14	Estimation of the total number of disease-causing mutations in ornithine transcarbamylase (OTC) deficiency. Value of the OTC structure in predicting a mutation pathogenic potential. Journal of Inherited Metabolic Disease, 2007, 30, 217-226.	3.6	40
15	First-time crystallization and preliminary X-ray crystallographic analysis of a bacterial-archaeal type UMP kinase, a key enzyme in microbial pyrimidine biosynthesis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1747, 271-275.	2.3	9
16	Understanding Carbamoyl Phosphate Synthetase Deficiency: Impact of Clinical Mutations on Enzyme Functionality. Journal of Molecular Biology, 2005, 349, 127-141.	4.2	33
17	The Crystal Structure of Pyrococcus furiosus UMP Kinase Provides Insight into Catalysis and Regulation in Microbial Pyrimidine Nucleotide Biosynthesis. Journal of Molecular Biology, 2005, 352, 438-454.	4.2	51
18	Site-directed Mutagenesis of Escherichia coli Acetylglutamate Kinase and Aspartokinase III Probes the Catalytic and Substrate-binding Mechanisms of these Amino Acid Kinase Family Enzymes and Allows Three-dimensional Modelling of Aspartokinase. Journal of Molecular Biology, 2003, 334, 459-476.	4.2	43